- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01611740
Contribution of Real Time Analyses of CARdio-RESpiratory Signals to the Diagnosis of Infection in PREterM Infants (CARESS_PREMI)
Contribution of Computerized Real Time Analyses of Cardio-respiratory Signals to the Diagnosis of Infection in Preterm Infants
Hospital-acquired infections are common complications in preterm infants. The diagnosis has to be fast and accurate. Indeed, the early identification of a suspected infection is very important, since the early administration of antibiotics lowers the risk of septic shock and improves long term outcome in the infected newborns who survive. Besides, a high specificity in the diagnosis of infection allows for the reduction of inappropriate treatment and thus prevents the emergence of antibiotic resistance.
The aim of this study is to develop a computer-assisted diagnosis tool, based on the real time analysis of cardio-respiratory signals, to aid the neonatologist in the diagnosis of infection of the preterm infant, at the bedside.
Study Overview
Status
Conditions
Detailed Description
Hospital-acquired infections increase morbidity and mortality in the preterm infants. Early diagnosis of infection is difficult mainly due to the poor performance of clinical signs and to the need for invasive procedure to get blood tests. However, early administration of antibiotics lowers the risk of septic shock and improves long term outcome in the infected newborns who survive. Many clinical features have been described, associated with an ongoing infection but they are inconsistent, variable and nonspecific. Similarly, many invasive laboratory tests have been proposed for the diagnosis of infection in the newborn but they all need blood sampling and none has a good predictive value.
The combined analysis of the heart rate and respiratory characteristics appears to be a promising tool for the diagnosis of infection in the preterm infants. These signals are non-invasively recorded and their computerized real time analyses would allow for a continuous assessment of the risk of infection.
The main objective is to test the hypothesis that the analyses of the variability of the cardiac cycle duration, the variability of the respiratory cycle amplitude and duration, and their relationships, can significantly improve the performance of the diagnosis of late onset infection in the preterm infant at the bedside in neonatal units.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59035
- CHU de Lille
-
Rennes, France, 35000
- CHU de Rennes
-
-
Maine Et Loire
-
Angers, Maine Et Loire, France, 49933
- Chu Angers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- preterm birth before < 32wks and > 24wks
- birth weight > 500g
- postnatal age> 3 days
- postconceptional age < 34wks
- parents information and collection of non-opposition
Exclusion Criteria:
- malformative syndrome
- severe neurological injury (IVH grade 4, cavitary periventricular leukomalacia, perinatal asphyxia post ischemia)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Preterm infants
Telemonitoring system prototype developed by INSERM U-642
|
Telemonitoring system prototype developed by INSERM U-642 with analysis of :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnosis of proven or suspected bacterial infection
Time Frame: Within the hospitalisation with an anticipated mean duration of 10 weeks
|
The primary outcome will be the efficiency (area under curve, sensitivity, specificity, false-positive and false-negative) of the combined analysis of heart rate and respiratory characteristics for the diagnosis of proven or suspected bacterial infection.
|
Within the hospitalisation with an anticipated mean duration of 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammation without proven or suspected bacterial infection defined as follows: a 6 hours period with CRP> 5 mg/L not classified as proven or suspected bacterial infection.
Time Frame: Within the hospitalisation with an anticipated mean duration of 2 to 10 weeks
|
We will investigate if this approach can discriminate an inflammation without proven or suspected bacterial infection defined as follows: a 6 hours period with CRP> 5 mg/L not classified as proven or suspected bacterial infection.
|
Within the hospitalisation with an anticipated mean duration of 2 to 10 weeks
|
Periods of discomfort defined as at least two EDIN scores above 3 in a 6 hours period
Time Frame: Within the hospitalisation with an anticipated mean duration of 2 to 10 weeks
|
The performance of a biomarker based on the computerized analyses of the cardiac and respiratory signals will also be tested for the detection of periods of discomfort defined as at least two EDIN scores above 3 in a 6 hours period.
|
Within the hospitalisation with an anticipated mean duration of 2 to 10 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-A00324-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infection
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
University of DuhokNot yet recruiting
-
Melinta Therapeutics, Inc.Department of Health and Human ServicesCompletedBacterial InfectionUnited States, Bulgaria
-
Kirby InstituteNot yet recruitingInvasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Centre Hospitalier Universitaire de BesanconUnknownAntibiotic Resistant Infection | Resistant Infection | Beta Lactam Resistant Bacterial Infection | Bacterial Resistance
-
University of OxfordCompletedPleural Infection | Pleural Infection BacterialUnited Kingdom
-
Jena University HospitalTerminatedSevere Bacterial InfectionBrazil, Colombia, Germany, Turkey
-
PfizerAllerganTerminatedGram-negative Bacterial InfectionUnited States, Hungary, Slovakia, Taiwan, India, Estonia, Greece, Italy
-
PfizerCompletedGram-negative Bacterial InfectionAustralia